von Bardeleben U, Holsboer F, Gerken A, Benkert O
Department of Psychiatry, University of Freiburg, Federal Republic of Germany.
Int Clin Psychopharmacol. 1989 Jan;4 Suppl 1:31-5.
According to severity of depressive symptomatology 14 inpatients with major depressive disorder (RDC) were assigned to 2 groups of 7 patients each with 6 of them receiving fluoxetine 60-80 mg/day and 1 receiving placebo in each group in a double-blind manner. After the treatment period of 35 days clinical improvement as assessed by standardized rating scales was more pronounced in the moderately depressed patients. There were no substantial side-effects in the 2 groups. These findings corroborate previous results from outpatient studies in more heterogeneous patient samples demonstrating safety and antidepressive efficacy of fluoxetine.
根据抑郁症状的严重程度，14名患有重度抑郁症（研究诊断标准）的住院患者被分为两组，每组7人，每组中有6人接受每天60 - 80毫克的氟西汀治疗，1人接受安慰剂治疗，采用双盲方式。在35天的治疗期后，通过标准化评定量表评估，中度抑郁患者的临床改善更为明显。两组均未出现明显副作用。这些发现证实了先前在更具异质性患者样本的门诊研究结果，证明了氟西汀的安全性和抗抑郁疗效。
